{"filing":{"accession_number":"0001213900-26-085432","cik":"0001506251","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"ea0300373-8k_citius.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/ea0300373-8k_citius.htm"},"events":[{"id":24784,"run_id":22474,"accession_number":"0001213900-26-085432","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure reports commercial progress for LYMPHIR, a recently launched oncology product, including 78% quarter-over-quarter growth in new institutional accounts, expansion to 42 institutions, and near-universal payer coverage. While this is a positive operational update on product commercialization rather than a discrete material event (M\u0026A, impairment, covenant breach, etc.), the metrics indicate material commercial momentum for a key revenue-generating product that would affect investor assessment of the registrant's operational trajectory and market penetration.","company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25456,"accession_number":"0001213900-26-085432","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports commercial progress for LYMPHIR, a recently launched oncology product, including 78% quarter-over-quarter growth in new institutional accounts, expansion to 42 institutions, and near-universal payer coverage. While this is a positive operational update on product commercialization rather than a discrete material event (M\u0026A, impairment, covenant breach, etc.), the metrics indicate material commercial momentum for a key revenue-generating product that would affect investor assessment of the registrant's operational trajectory and market penetration.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:21:29.121152+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25456,"accession_number":"0001213900-26-085432","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports commercial progress for LYMPHIR, a recently launched oncology product, including 78% quarter-over-quarter growth in new institutional accounts, expansion to 42 institutions, and near-universal payer coverage. While this is a positive operational update on product commercialization rather than a discrete material event (M\u0026A, impairment, covenant breach, etc.), the metrics indicate material commercial momentum for a key revenue-generating product that would affect investor assessment of the registrant's operational trajectory and market penetration.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:21:29.121152+00:00","company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","filing_date":"2026-08-05"}]}